LUPINNSELupin Limited· PharmaceuticalsMediumNeutral
Announced Fri, 17 Apr · 17:15 IST

Lupin Limited has informed the Exchange about Incorporation of a wholly owned subsidiary in Thailand.

Strategic Transactions View source PDF

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹2322.50
prior close
₹2323.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.4+0.5+0.4-0.4-0.5+1.1-1.1-0.1-0.8-3.1-1.7+0.9+7.1
Up moveDown movePending
AI summary

Lupin Limited has incorporated a wholly owned subsidiary named 'Lupin (Thailand) Limited' on April 17, 2026. The new entity will operate in the pharmaceutical industry, focused on importing, marketing, promoting, distributing, and selling pharma products in Thailand. It has been set up with a paid-up capital of 3 million Thai Baht (600,000 shares at 5 Baht each), with Lupin holding 100% of the shareholding. The investment was made in cash, and no government or regulatory approvals were required for the incorporation.

Likely market impact

This move signals Lupin's strategic push to expand its direct presence in the Southeast Asian market, which could help the company grow its international pharmaceutical footprint over time. For shareholders, it is a positive long-term signal of international expansion, though the capital involved is small and the immediate financial impact on earnings is likely negligible.